DFTX
NASDAQDefinium Therapeutics Inc.
SectorHealth CareIndustry Medicinal Chemicals and Botanical Products
Price$35.10-0.08 (-0.23%)
01:30 PM07:45 PM
News · 26 weeks99+186%
2026-04-122026-10-04
Mix4790d
- Insider18(38%)
- Other17(36%)
- SEC Filings8(17%)
- Analyst2(4%)
- Earnings1(2%)
- Leadership1(2%)
Latest news
25 items- INSIDERChief Medical Officer Karlin Daniel sold $396,894 worth of shares (10,853 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 792,846 units (SEC Form 4) (withholding obligation)4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
- INSIDERChief Executive Officer Barrow Robert sold $1,153,784 worth of shares (31,550 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 2,213,090 units (SEC Form 4) (for withholding tax)4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
- INSIDERChief Commercial Officer Wiley Matthew T. sold $113,257 worth of shares (3,097 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 0.86% to 359,036 units (SEC Form 4) (for tax liability)4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
- INSIDERChief Legal Officer Sullivan Mark sold $513,845 worth of shares (14,051 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 494,228 units (SEC Form 4) to satisfy withholding tax4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
- INSIDERChief Financial Officer Roberts Brandi sold $123,497 worth of shares (3,377 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 0.85% to 394,528 units (SEC Form 4) (withholding tax)4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
- PRDefinium Therapeutics Announces New Employee Inducement GrantsDefinium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to fifteen newly hired non-executive employees consisting of options to purchase an aggregate of 334,810 common shares of the Company (the "Options") with effective grant dates of September 28, 2026. The Options have an exercise price equal to the closing price of Definium’s common shares on the date of the grants, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the g
- SECSEC Form 144 filed by Definium Therapeutics Inc.144 - Definium Therapeutics, Inc. (0001813814) (Subject)
- SECSEC Form 144 filed by Definium Therapeutics Inc.144 - Definium Therapeutics, Inc. (0001813814) (Subject)
- SECSEC Form 144 filed by Definium Therapeutics Inc.144 - Definium Therapeutics, Inc. (0001813814) (Subject)
- INSIDERDirector Vallone Carol A exercised 1,086 shares at a strike of $35.52, increasing direct ownership by 5% to 22,296 units (SEC Form 4)4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
- INSIDERDirector Krebs Andreas exercised 1,629 shares at a strike of $35.52, increasing direct ownership by 8% to 21,402 units (SEC Form 4)4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
- INSIDERChief Executive Officer Barrow Robert was granted 750,000 shares, increasing direct ownership by 50% to 2,244,640 units (SEC Form 4)4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
- INSIDERChief Legal Officer Sullivan Mark was granted 125,000 shares, increasing direct ownership by 33% to 508,279 units (SEC Form 4)4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
- INSIDERChief Financial Officer Roberts Brandi was granted 125,000 shares, increasing direct ownership by 46% to 397,905 units (SEC Form 4)4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
- INSIDERChief Commercial Officer Wiley Matthew T. was granted 125,000 shares, increasing direct ownership by 53% to 362,133 units (SEC Form 4)4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
- INSIDERChief Medical Officer Karlin Daniel was granted 200,000 shares, increasing direct ownership by 33% to 803,699 units (SEC Form 4)4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
- SECDefinium Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Definium Therapeutics, Inc. (0001813814) (Filer)
- PRDefinium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety DisorderStudy met primary and all key secondary efficacy endpoints; Panorama is the second positive Phase 3 trial for DT120 ODT in GAD and the third positive Phase 3 trial for DT120 ODT Participants receiving DT120 ODT 100 µg achieved a statistically significant reduction in Hamilton Anxiety Rating Scale (HAM-A) score, with a placebo-adjusted change of 5.1 points from baseline at Week 12 (p<0.0001, Cohen’s d=0.64) DT120 ODT 100 µg was generally well tolerated, with a safety profile consistent with prior clinical experience Pre-NDA meeting scheduled in 4Q 2026; NDA filing anticipated in 1H 2027 Company to host webcast today at 8 am EDT Definium Therapeutics, Inc. (NASDAQ:DFTX) ("Definium"
- PRDefinium Therapeutics Announces New Employee Inducement GrantsDefinium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to three newly hired non-executive employees consisting of options to purchase an aggregate of 56,650 common shares of the Company (the "Options") with effective grant dates of September 14, 2026. The Options have an exercise price equal to the closing price of Definium’s common shares on the date of the grants, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the gran
- PRDefinium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026Company to host webcast tomorrow at 8:00 a.m. EDT Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a live webcast tomorrow at 8 a.m. EDT to discuss topline results from Panorama, the Company’s second Phase 3 study of DT120 (lysergide) Orally Disintegrating Tablet (ODT) in adults with generalized anxiety disorder (GAD). Webcast Details Listeners can register for the webcast via this link. Analysts wishing to participate in the question-and-answer session should use this li
- SECDefinium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Definium Therapeutics, Inc. (0001813814) (Filer)
- PRDefinium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 ResultsSecond FDA Breakthrough Therapy designation for DT120 reinforces its potential across MDD and generalized anxiety disorder (GAD), two disorders with significant unmet need Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for DT120 (lysergide) ODT. The designation was supported by the significant unmet medical need in MDD and results from the Company's Phase 3 Emerge study, in which a single 100 µg dos
- INSIDERChief Executive Officer Barrow Robert was granted 40,000 shares and sold $721,733 worth of shares (19,023 units at $37.94) as part of a pre-agreed trading plan, increasing direct ownership by 1% to 1,494,640 units (SEC Form 4) (tax withholding)4 - Definium Therapeutics, Inc. (0001813814) (Issuer)
- PRDefinium Therapeutics Announces New Employee Inducement GrantsDefinium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to three newly hired non-executive employees consisting of options to purchase an aggregate of 88,900 common shares of the Company (the "Options") with effective grant dates of August 31, 2026. The Options have an exercise price equal to the closing price of Definium’s common shares on the date of the grants, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant a
- PRDefinium Therapeutics to Participate at Upcoming Investor Conferences and EventsDefinium Therapeutics, Inc. (NASDAQ:DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in the following investor conferences and events: Stifel Hosted Webinar: Definium Therapeutics Virtual Fireside Chat Presentation Date and Time: Tuesday, September 1, 2026 at 1:00 PM ET Moderator: Paul Matteis, Head of Therapeutics Research Focus: Discussion of Definium’s positive topline results from the Phase 3 Voyage study of DT120 ODT in generalized anxiety
DFTX FAQ
5 questionsWhere does DFTX stock trade?
Definium Therapeutics Inc. (DFTX) is listed on NASDAQ.What sector and industry is DFTX in?
Definium Therapeutics Inc. operates in the Health Care sector, Medicinal Chemicals and Botanical Products industry.What are analysts saying about DFTX?
Definium Therapeutics Inc. has had 7 recent analyst actions on file. The most recent action was from BofA Securities: Buy on 2026-08-18. Recent price targets range from $2500.00 to $4900.00.What companies are similar to DFTX?
Notable peers in the same industry include PM (Philip Morris International Inc), BTI (British American Tobacco Industries p.l.c.), MO (Altria Group Inc.), RGC (Regencell Bioscience Holdings Limited), CGC (Canopy Growth Corporation). Compare DFTX side-by-side with any of them on Quantisnow.How can I track DFTX on Quantisnow?
Quantisnow aggregates Definium Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DFTX to receive live email and push alerts on every new disclosure.